Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.
about
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based methodPhase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Relevance of timing for determination of posaconazole plasma concentrationsPharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteersPosaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Use of posaconazole in the treatment of invasive fungal infections.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Triazole antifungal agents in invasive fungal infections: a comparative review.Fungal infections of the skin and nail: new treatment options.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections.Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Posaconazole: a next-generation triazole antifungal.The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation.Posaconazole (Noxafil): a new triazole antifungal agent.Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.Posaconazole: An Update of Its Clinical Use.Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
P2860
Q33798286-C1F3A2A2-B387-48AD-AD27-28810027248DQ33798313-D8E6A03D-8C57-48F1-A90A-9047AF78EA8FQ34108484-DFEFD58C-0522-45DA-8D3C-B40FDE606EEAQ34299092-14D15AB2-1F5D-4F2E-8975-329756185E32Q35026481-9A366FD8-5E28-4C31-9FF8-40435CF55318Q35065721-C1F4F1ED-7869-4B71-A777-CABB6738894DQ35105840-FBFB4CE4-7B95-4E09-97D4-731397081321Q35607672-7580614B-81F0-4959-B4BB-4D328347F749Q35635971-20EECB83-2A69-45BE-9E06-9A55B22117D0Q35941414-A19296E6-A572-439A-B8A6-D5D7264EFCA4Q36171677-5932FED0-BCC9-4D55-A1CD-59F60AA43FDEQ37055215-7E99CF55-44E5-4EA4-9A6E-78F936A6EB85Q37115829-3CC31569-27D6-4F88-9E53-DD85C6D9DE0DQ37247780-A396F669-CC26-4414-ACAA-387DE94180A9Q37404840-19CD0C06-5586-4B7E-A1E6-6F35DF5F8E49Q37409875-C0F9645E-13B4-42D6-BDCF-0DBC8664DC04Q37469829-22C99CA7-2D57-4C69-8E7B-253AF53D0991Q37810083-5E7A303E-BE61-44EF-A42D-5ED4C65AF6BBQ37904672-91435C76-10DC-4276-9C5E-FE9F4E668245Q37964703-715DF0F6-5791-4040-8738-3F80C43E02F2Q38252946-A584DF3A-2E13-42D7-9A16-A037900DE28FQ38284468-FAD322E0-53FE-40FA-8B07-9BFEE9412107Q38321383-C19829D5-234F-4B68-B28E-92BD684DDBC2Q38751500-637AA8A5-B0FB-4432-9234-CAC18E213147Q40188974-3317E2B0-945B-4C8D-821C-AFAAB3E88569Q40255550-77529E2C-0DFD-489B-8D56-1136488033DFQ40413232-380D0B8E-A6CD-4B7A-AEA5-0EEC3EBBC679Q40452729-7373E0D3-B09E-47F4-AD8E-D76ACCC86506Q40892430-B231508E-C889-4919-9F5B-493502E28D76Q41993016-32A43492-0437-41FC-8703-1003D355E64DQ42144246-E7CC2351-B14C-402B-9CDD-44032D0F1601Q44162406-758C46B5-BAAE-4C9A-9ABD-B00C0DFD339BQ46341880-C57CBD27-02A5-43E4-9936-F2593F677482Q46840248-EB040AE8-17C6-4713-B229-BE66D543C98AQ46879963-89054E82-38C8-41B5-BCF3-D1C707C5ED7A
P2860
Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effect of a nutritional supple ...... tration to healthy volunteers.
@ast
Effect of a nutritional supple ...... tration to healthy volunteers.
@en
Effect of a nutritional supple ...... tration to healthy volunteers.
@nl
type
label
Effect of a nutritional supple ...... tration to healthy volunteers.
@ast
Effect of a nutritional supple ...... tration to healthy volunteers.
@en
Effect of a nutritional supple ...... tration to healthy volunteers.
@nl
prefLabel
Effect of a nutritional supple ...... tration to healthy volunteers.
@ast
Effect of a nutritional supple ...... tration to healthy volunteers.
@en
Effect of a nutritional supple ...... tration to healthy volunteers.
@nl
P2093
P2860
P1476
Effect of a nutritional supple ...... tration to healthy volunteers.
@en
P2093
Angela Calzetta
Angela Sansone-Parsons
Bhavna Kantesaria
David Wexler
Gopal Krishna
Marc A Saltzman
Mitchell A Rosenberg
P2860
P304
P356
10.1128/AAC.50.5.1881-1883.2006
P407
P577
2006-05-01T00:00:00Z